Breast Cancer

A real-world investigation has found that CDK4/6 inhibitor treatment outcomes are worse in patients with germline BRCA mutation–positive metastatic breast cancer than in patients with germline BRCA wild-type disease and unclear germline BRCA status, implying possible changes in tumor biology.
PARP inhibitors offer the possibility of biomarker-targeted treatment for breast cancer. Therefore, it is necessary to quickly identify which patients may benefit from treatment and to guarantee that genetic testing is available.
Adding CDK4/6 inhibitors to fulvestrant resulted in an improvement in overall survival. These findings back up the current standard of care of CDK4/6 inhibitors plus fulvestrant for patients with HR-positive, HER2-negative, advanced breast cancer.
In a real-world study, more than 60% of the HR-positive, HER2-negative advanced breast cancer samples had ≥1 disease-related poor prognostic factors. The need for more effective CDK4/6 inhibitor medication in these individuals is highlighted by their increased pain and impaired performance status.
Results of a recent web-based survey show that survey respondents are in favor of several changes in breast cancer treatment during COVID-19. These changes must be discussed on a local level, taking into consideration the infrastructure and resources available.
A recent study found that omega-6 PUFA supplementation surprisingly reduced cancer-related fatigue in exhausted American breast cancer survivors when compared with omega-3 PUFA supplementation, and that omega-6 PUFA supplementation surprisingly lowered proinflammatory blood markers, completely against expectations.
The phase 3 OlympiA trial showed olaparib had impressive results versus placebo, with improvement in disease-free survival with adjuvant olaparib in early-stage, HER2-negative breast cancer and BRCA1/2 mutations. This highlights the need to test for BRCA1/2 mutations to determine if patients qualify for olaparib.
In the phase 3 ASCENT study, Trodelvy was demonstrated to significantly enhance quality of life compared with standard of care in second-line and beyond metastatic triple-negative breast cancer.
Patients need to know why they are taking Trodelvy, the indications for which include metastatic triple-negative breast cancer. They should be educated on the benefits of Trodelvy along with potential side effects associated with treatment, including guidance on how they can manage those adverse events.
Trodelvy Access Support is a patient access and reimbursement support program that will help you and your patients understand reimbursement and specific coverage guidelines for Trodelvy.
Page 4 of 20
Results 31 - 40 of 196

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country